21:17:43 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Nightingale Health är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.

Kalender

2023-03-02 Kvartalsrapport 2023-Q2
2022-11-17 Årsstämma 2023
2022-10-25 Ordinarie utdelning HEALTH 0.00 EUR
2022-09-29 Bokslutskommuniké 2022
2022-02-24 Kvartalsrapport 2022-Q2
2021-10-29 Ordinarie utdelning HEALTH 0.00 EUR
2021-10-28 Årsstämma 2022
2021-09-15 Bokslutskommuniké 2021
2021-10-07 08:30:00

Press release, 7 October 2021 at 9:30 a.m. (EEST)

Nightingale Health Plc ("Nightingale") has received a CE marking for its at-home blood collection kit that it uses in its at-home solution. The at-home blood collection kit is CE marked under the category of in vitro diagnostic medical devices, and the CE marking covers the packaging, the equipment used for the blood collection and instructions for use.

Nightingale has previously distributed the at-home blood collection kit in its at-home pilot under the CE marking registered by the device manufacturer, but now the CE marking registered by Nightingale enables Nightingale to operate more independently and rapidly when scaling its at-home solutions to different international markets. Registering the CE marking for the at-home blood collection kit allows Nightingale to make changes to the product according to a flexible process, which makes it possible to adjust to the needs of different markets and business partners.

Teemu Suna, CEO and Co-founder of Nightingale:

"Our own CE marking for the at-home blood collection kit is an important part of the global expansion plan of the at-home testing offering, as having more control of the product enables rapid market entries by adapting to local needs. Applying for the CE marking was a systematic extension to our quality strategy, which ensures that our products and services always correspond to the highest quality standards."

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

About Nightingale

Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. The wide-ranging disease risk predictions provided by Nightingale consist of two interconnected factors: The extensive blood analysis technology developed by Nightingale and a large amount of data on health events. Nightingale helps people make better personal health decisions and connects the health industry to offer their services for individuals' preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone.